A recent study reveals that individuals who discontinue new GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass much more quickly than those who stop conventional lifestyle plans.
Published data in a prominent health publication demonstrates that while obese people can lose about a fifth of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"People purchasing such drugs must be informed of the danger of quick rebound weight gain when the medication is stopped," warns expert Dr. Susan Jebb.
This pace of recovery suggests a return to pre-treatment weight within about 18 months.
Weighing Approaches
The study, which reviewed 37 of studies involving over 9,000 of participants, contrasted the effects of the injectable medications with conventional dieting.
The team point out that people who shed pounds through dieting usually have a slower creep back—perhaps 100 grams monthly—after stopping.
Understanding the Quick Regain
Nutrition scientists believe the way of the injections explains the amplified regain.
The injections copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Sustained high doses of the hormone levels several times higher than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and could reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication results in hunger is unsuppressed, making binge eating far more likely."
A Chronic Condition?
Health authorities recommend the jabs for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Professionals say that, due to the high risk of weight regain, the treatment might need to be life-long.
This view is reinforced by pharmaceutical companies, who state that the results "highlight the chronic nature of obesity," akin to managing conditions like diabetes.
User Testimonies
Users who have stopped the medication report a intense resurgence of hunger.
"It was like a switch that goes on and you become starving," recalled an individual.
This difficulty is exacerbated if individuals have not developed lasting dietary or behavioural changes during treatment.
Widespread Interest
Recent estimates show that millions of people in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Adoption is higher among females than males.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
In conclusion, researchers stress that while these medications are effective agents for weight loss, they are not a permanent cure and lasting health benefits likely depends on combined behavioural management.
